Grand Rounds—City Hospital, Nottingham: A complicated case of community acquired pneumonia

BMJ

Volumn 312, Issue 7035, 1996, Pages 899-

  Johnson, S R ^a   Pavord, I D ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CLINICAL OBSERVATION; CLINICAL STUDY; COMMUNICABLE DISEASE; DIAGNOSIS; FEMALE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; ORNITHOSIS; PNEUMONIA; AMNESIA; CHLAMYDOPHILA PSITTACI; FEVER; FLUID BALANCE; HEART VENTRICLE FIBRILLATION; HOSPITAL ADMISSION; HYPOTENSION; INTENSIVE CARE; INTERMITTENT POSITIVE PRESSURE VENTILATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LUNG CONGESTION; MYOCARDIAL DISEASE; PRIORITY JOURNAL; TACHYCARDIA;

ADULT; ARRHYTHMIA; COMMUNITY-ACQUIRED INFECTIONS; DEAFNESS; FEMALE; HUMANS; HYPERBILIRUBINEMIA; PNEUMONIA; PSITTACOSIS;

ALFENTANIL; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME; DOBUTAMINE; DOPAMINE; DOXYCYCLINE; ERYTHROMYCIN; FUROSEMIDE; INOTROPIC AGENT; RIFAMPICIN; SUCRALFATE;

EID: 0030571858     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7035.899     Document Type: Article

References (18)

1. Ortqvist A. Initial investigation and treatment of the patient with severe community acquired pneumonia. Semin Respir Infect 1994; 9: 166–79.
2. Ortqvist A, Sterner G, Axel Nilsson J. Severe community acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985; 17: 377–86.
3. Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community acquired pneumonia. Journal Infect 1985; 10: 204–21.
4. Sorenson J, Cederholm I, Carlsson C. Pneumonia a deadly disease despite intensive care treatment. Scand J Infect Dis 1986; 18: 329–35.
5. Sorenson J, Forsberg P, Hakanson E, Maller R, Sederholm C, Soren L, et al. A new diagnostic approach to the patient with severe pneumonia. Scand J Infect Dis 1989; 21: 33–41.
6. Alkhaayer M, Jenkins PF, Harrison BDW. The outcome of community acquired pneumonia treated on the intensive care unit. Respir Med 1990; 84: 13–16.
7. British Thoracic Society Research Committee. The aetiology, management and outcome of severe community acquired pneumonia on the intensive care unit. Respir Med 1992; 86: 7–13.
8. Wreghitt T. Chlamydial infection of the respiratory tract. Commun Dis Rep CDR Rev 1993; 3: R119–R124.
9. Te Boerkhorst T, Urlus M, Doesburg W, Yap SH, Goris RJA. Etiologic factors of jaundice in severely ill patients. J Hepatol 1988; 7: 111–7.
10. Acocella G. Pharmacokinetics and metabolism of rifampicin in humans. Rev Infect Dis 1983; 5: S428–S432.
11. Acocella G, Lamarina A, Nicolis FB, Pagani V, Segre G. Kinetic studies on rifampicin II multicompartmental analysis of the serum, urine and bile concentrations in normal subjects treated for one week. Eur J Clin Pharmacol 1972; 5: 111–5.
12. Hubbard RB, Mathur RM, Macfarlane JT. Severe community acquired legionella pneumonia: treatment, complications and outcome. Q J Med 1993; 86: 327–32.
13. Haefeli WE, Schoenenberger RA, Weiss PH, Ritz R. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med 1992; 18: 469–73.
14. Gallagher KL, Jones KJ. Frusemide induced ototoxicity. Ann Intern Med 1979; 91: 744–5.
15. Umstead GS, Neuman KH. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with acute hepatic dysfunction. Arch Intern Med 1986; 146: 897–9.
16. Macfarlane JT. An overview of community acquired pneumonia with lessons learnt from the British Thoracic Society study. Semin Resp Infect 1994; 9: 153–65.
17. Smyth ET, Pavord ID, Wong CS, Wisniewski AFZ, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993; 306: 543–5.
18. Lipworth BJ, McDevitt DG, Struthers AD. Electrocardiographic changes induced by inhaled salbutamol after treatment with bendrofluazide: effects of replacement therapy with potassium, magnesium and triamterene Clin Sci (Colch) 1990; 78: 255–9.